A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is a cAMP-regulated ion channel used for the transport of anions across epithelial cells [1]. Mutations in this gene result in a thickening of mucosal secretions, primarily in the respiratory and gastrointestinal systems [1]. Common clinical manifestations of this disease include, but are not limited to, chronic polymicrobial sino-pulmonary infections, male infertility, decreased lung function, and pancreatic insufficiency [1]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 22, 2021 Category: Respiratory Medicine Authors: Lo M. Sosinski, Christian Martin H, Kerri A. Neugebauer, Lydia-Ann J. Ghuneim, Douglas V. Guzior, Alicia Castillo-Bahena, Jenna Mielke, Ryan Thomas, Marc McClelland, Doug Conrad, Robert A. Quinn Source Type: research

Urinary sodium/creatinine ratio is a predictor for fractional sodium excretion and related to age in patients with cystic fibrosis
As result of the cystic fibrosis transmembrane regulator (CFTR) dysfunction, patients with cystic fibrosis (CF) lose 2 –4 times more salt in their sweat [1]. Siegentahler et al. demonstrated that CF patients, in contrast to healthy controls, were unable to decrease salt losses in sweat when confronted with salt deprivation [2]. Hyponatremic, hypochloremic alkalosis with or without hypokalemia, also known as pseud o-Bartter syndrome, can be observed in patients with CF confronted with situations leading to inadequate salt and fluid intake or increased losses through the gastro-intestinal tract or sweating. (Sourc...
Source: Journal of Cystic Fibrosis - November 18, 2021 Category: Respiratory Medicine Authors: Dimitri Declercq, Lieselot Peremans, Michiel Glorieus, Yannick Vande Weygaerde, Heidi Schaballie, Eva Van Braeckel, Evelien Snauwaert, Sabine Van daele, Stephanie Van Biervliet Source Type: research

Quality of life is poorly correlated to lung disease severity in school-aged children with cystic fibrosis
The median predicted age of survival with Cystic Fibrosis (CF) has increased substantially in the past decade [1], and is now estimated at close to 50 years [2]. This increased survival comes with a significant treatment burden of daily physiotherapy, antibiotic regimens, enzyme replacement and frequent hospital visits which directly impact the quality of life of children and their caregivers and demand for psychological support for patients and families living with CF has heightened [3]. Attention has shifted towards health-related quality-of-life (HRQOL) leading to its recognition as an important health outcome measure i...
Source: Journal of Cystic Fibrosis - November 17, 2021 Category: Respiratory Medicine Authors: Phillip Pattie, Sarath Ranganathan, Joanne Harrison, Suzanna Vidmar, Graham L Hall, Rachel E. Foong, Alana Harper, Kathryn Ramsey, Danielle Wurzel, AREST CF Source Type: research

Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip
Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a membrane protein with chloride channel function [1]. In the bronchial epithelium, CFTR dysfunction causes contraction of the periciliary volume; accumulation of dense mucus, promoted by hypersecretion of the mucins MUC5AC and MUC5B and by defective mucociliary transport; chronic infection and neutrophilic inflammation, leading to respiratory insufficiency and death [2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 16, 2021 Category: Respiratory Medicine Authors: Roberto Plebani, Ratnakar Potla, Mercy Soong, Haiqing Bai, Zohreh Izadifar, Amanda Jiang, Renee N. Travis, Chaitra Belgur, Alexandre Dinis, Mark J. Cartwright, Rachelle Prantil-Baun, Pawan Jolly, Sarah E. Gilpin, Mario Romano, Donald E. Ingber Tags: Original Article Source Type: research

Macrophages from gut-corrected CF mice express human CFTR and lack a pro-inflammatory phenotype
Chronic airway inflammation underpins the progression of CF lung disease and is consequently a major focus of CF research and an important therapeutic target. There is ample evidence of dysregulated inflammatory pathways in immune cells derived from people with CF and the observation of functional CFTR expression in non-epithelial cells has uncovered a direct role for the basic defect in immune cell dysfunction in CF, particularly in monocytes and macrophages [1 –3]. Rollout of disease-modifying CFTR modulators to the vast majority of people with CF may now place further emphasis on animal models to provide a means o...
Source: Journal of Cystic Fibrosis - November 16, 2021 Category: Respiratory Medicine Authors: Jonathan L Gillan, Gareth R Hardisty, Donald J Davidson, Robert D Gray Source Type: research

Management of Cystic Fibrosis during COVID-19: Patient Reported Outcomes based remote follow-up among CF patients in Denmark – A feasibility study
Cystic fibrosis (CF) requires frequent outpatient visits with monitoring of lung function, microbiology, and nutritional status. Treatment burden has increased over recent years, and most patients take multiple drugs, several times daily [1]. Treatment regimens including mucolytics, antibiotics, pancreatic enzymes, and insulin, have addressed organ system manifestations rather than treating the underlying ion channel dysfunction. In combination with exercise and physiotherapy, these treatments have been considered to be the best supportive care and have increased life expectancy significantly [2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 13, 2021 Category: Respiratory Medicine Authors: Lotte Rodkj ær, Majbritt Jeppesen, Liv Schougaard Source Type: research

Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment
Cystic fibrosis (CF [MIM: 219,700]) was an early Mendelian condition for which the underlying gene – cystic fibrosis transmembrane conductance regulator (CFTR) – was mapped and sequenced [1]. This allowed recognition that CFTR variants severely reduced function of the CFTR protein, an ion channel that spans the membrane of epithelial cells. Individuals with CF typically exhibit multi-organ di sease and the majority experiences substantial morbidity and early mortality due to respiratory failure [2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 12, 2021 Category: Respiratory Medicine Authors: Karen S Raraigh, Melis A Aksit, Kurt Hetrick, Rhonda G Pace, Hua Ling, Wanda O'Neal, Elizabeth Blue, Yi-Hui Zhou, Michael J Bamshad, Scott M Blackman, Ronald L Gibson, Michael R Knowles, Garry R Cutting Source Type: research

Quality of home spirometry performance amongst adults with cystic fibrosis
In pulmonary function laboratories, spirometry is usually performed under the supervision of a trained respiratory scientist to optimise quality and ensure acceptability and repeatability of results as outlined by the 2019 American Thoracic Society (ATS) and European Respiratory Society (ERS) Statement [1]. Prior studies have raised concerns regarding the usefulness of spirometry in the community without greater attention to quality assurance and training, including in primary care practices [2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 10, 2021 Category: Respiratory Medicine Authors: Jody M Bell, Sheila Sivam, Ruth L Dentice, Tiffany J Dwyer, Helen E Jo, Edmund M Lau, Phillip A Munoz, Samantha A Nolan, Nicole A Taylor, Simone K Visser, Veronica A Yozghatlian, Keith KH Wong Source Type: research

Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge
Sputum biomarkers hold promise as a direct measure of inflammation within the cystic fibrosis (CF) lung, but variability in study design and sampling methodology have limited their use. A full evaluation of the reliability, validity and clinical relevance of individual biomarkers is required to optimise their use within CF clinical research. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 9, 2021 Category: Respiratory Medicine Authors: Agathe Lepissier, Charlotte Addy, Kate Hayes, Sabrina Noel, St éphanie Bui, Pierre-Régis Burgel, Lieven Dupont, Olaf Eickmeier, Michael Fayon, Teresinha Leal, Carlos Lopes, Damian G. Downey, Isabelle Sermet-Gaudelus Source Type: research

Final results of the southwest German pilot study on cystic fibrosis newborn screening – Evaluation of an IRT/PAP protocol with IRT-dependent safety net
Agreement on the benefits of cystic fibrosis (CF) newborn screening (NBS) led to widespread implementation of CFNBS in many countries (e.g. [1]). In Germany, nationwide CFNBS was implemented on September 1st 2016 after a long decision process. Before that, it was uncertain for a long time whether and how genetic screening for CF could be used in Germany. In addition, there was great interest in a future CF screening algorithm that avoids detection of healthy carriers for CF and detects as few as possible of the newborns later designated as CFSPID (CF screening positive, inconclusive diagnosis). (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 8, 2021 Category: Respiratory Medicine Authors: Olaf Sommerburg, Mirjam Stahl, Susanne H ämmerling, Gwendolyn Gramer, Martina U. Muckenthaler, Jürgen Okun, Dirk Kohlmüller, Margit Happich, Andreas E. Kulozik, Marcus A. Mall, Georg F. Hoffmann Tags: Original Article Source Type: research

The effectiveness of exercise interventions to increase physical activity in Cystic Fibrosis: A systematic review
Cystic Fibrosis (CF) is a chronic and life limiting condition. Improved CF management has led to a median survival age in 2019 of 48.4 years [17]. CF is a complex, multisystem disease, characterised by recurrent pulmonary infections and nutritional deficiencies [9]. The course of CF progression is denoted by exacerbations which can cause increased coughing, increased energy expenditure with a reduced body mass index (BMI) and declining pulmonary function [35]. As a result, people with CF (PWCF) may avoid or limit physical activity (PA) due to factors such as fatigue and shortness of breath resulting in progressive reductio...
Source: Journal of Cystic Fibrosis - November 6, 2021 Category: Respiratory Medicine Authors: M. Curran, AC. Tierney, B. Button, L. Collins, L. Kennedy, C. McDonnell, B. Casserly, R. Cahalan Source Type: research

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy
Some prescription medications can cause altered mental status (AMS) by stimulating the brain and improperly inhibiting neuron excitability.[1,2,3,4] This can result in symptoms of disoriented speech, confusion, and amnesia. Active stimulant medications may cause other critical symptoms, and in severe cases can require rehabilitation therapy and supportive care. A snapshot of commonly prescribed drug classes known to cause AMS can be found in Table  1. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - November 3, 2021 Category: Respiratory Medicine Authors: Suyeon Heo, David C. Young, Julie Safirstein, Brian Bourque, Martine H. Antell, Stefanie Diloreto, Shannon M. Rotolo Tags: Short Communication Source Type: research

CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis
Patients with pancreatic insufficient cystic fibrosis (PI-CF) rarely develop acute pancreatitis (AP) due to insufficient residual acinar tissue [1]. CFTR modulators, such as ivacaftor (IVA) (Kalydeco ™) and lumacaftor-ivacaftor (LUM-IVA) (Orkambi™) have dramatically improved health outcomes in CF [2]. Of particular interest are reports of at least partial restoration of exocrine pancreatic function in PI-CF patients on IVA started before age 6 [3]. Recently, clinicians have observed AP in PI -CF patients after initiating CFTR modulator therapy. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 31, 2021 Category: Respiratory Medicine Authors: Michelle J. Gould, Haley Smith, Jonathan H Rayment, Helen Machida, Tanja Gonska, Gary J. Galante Tags: Short Communication Source Type: research

Arm muscle area for the longitudinal assessment of nutritional status in paediatric patients with cystic fibrosis - A single centre experience
In the care of children with cystic fibrosis (CF), clinicians aim to ensure that their patients have healthy lungs and normal weight when they pass into adulthood. Preventing nutritional deficits is associated with improved growth and respiratory function and is likely to improve prognosis [1]. Accordingly, height and weight are closely monitored throughout childhood. From the age of 2 years, BMI should also be calculated, as stated in the European Standards of Care [2]. Children and adolescents with cystic fibrosis should achieve the 50th percentile for BMI. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 30, 2021 Category: Respiratory Medicine Authors: Helmut Ellemunter, Markus Dumke, Gratiana Steinkamp Tags: Original article Source Type: research

Unexpected associations between respiratory viruses and bacteria with Pulmonary Function Testing in children suffering from Cystic Fibrosis (MUCOVIB study)
Cystic fibrosis (CF) is a common inherited disease affecting over 70,000 people worldwide [1]. Despite progress in management, pulmonary exacerbations and resultant respiratory failure are still associated with significant morbidity and mortality [2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 29, 2021 Category: Respiratory Medicine Authors: Valentin Scherz, Giorgia Caruana, Patrick Taff é, René Brouillet, Claire Bertelli, Katia Jaton-Ogay, Yves Fougère, Klara M. Posfay-Barbe, Anne Mornand, Isabelle Rochat-Guignard, Aline Mamin, Laurent Kaiser, Gilbert Greub, Sandra A. Asner Source Type: research

No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.
Clofazimine is an antimycobacterial drug which is used for the treatment of non-tuberculous mycobacterium (NTM). In August 2019 clofazimine got a positive opinion for orphan designation for the treatment of NTM lung disease by the European Medicines Agency. In vitro clofazimine has been characterized as an inhibitor of cytochrome P450 (CYP)3A4/5, 2C8 and 2D6. In previously performed static and physiologically based pharmacokinetic (PBPK) modeling prediction studies an interaction between clofazimine and midazolam, a probe substrate for CYP3A4, was characterized. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 29, 2021 Category: Respiratory Medicine Authors: S.E.M. Vonk, S.W.J. Terheggen-Lagro, L.M. Mouissie, R.A.A. Math ôt, E.M. Kemper, Amsterdam Mucociliary Clearance Disease (AMCD) research group Tags: Case Report Source Type: research

When CFSPID becomes CF
A 7-year old Hispanic boy was referred to our cystic fibrosis (CF) clinic for evaluation of recurrent pneumonias and chronic cough. He had had a positive CF newborn screening (CF NBS) and was lost to follow up for 6 years. His CF NBS report from the California Department of Public Health showed immunoreactive trypsinogen (IRT) of 70 ng/ml and two CFTR variants: G542X and 5T;TG12, categorized as CF-causing and variant of varying clinical consequence, respectively, according to CFTR2 classification (www.cftr2.org). (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 28, 2021 Category: Respiratory Medicine Authors: Daniella Ginsburg, Choo Phei Wee, Maria Carmen Reyes, John J. Brewington, Danieli B. Salinas Tags: Short Communication Source Type: research

CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β-adrenergic sweat rate assay
Cystic fibrosis (CF) is a multisystem disorder of apical epithelial transport of chloride and bicarbonate ions [1] that is caused by biallelic mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene [2,3]. p.Phe508del is the most common CFTR mutation [3 –5]. Combination treatment with the folding correctors tezacaftor (TEZ), elexacaftor (ELX) and the gating potentiator ivacaftor (IVA) restored p.Phe508del CFTR function in human nasal and bronchial epithelial cells in vitro [6,7] and conferred clinical benefit in lung function, body weight and qua lity of life to CF patients with one or two p....
Source: Journal of Cystic Fibrosis - October 28, 2021 Category: Respiratory Medicine Authors: Sophia Theres Pallenberg, Sibylle Junge, Felix C Ringshausen, Annette Sauer-Heilborn, Gesine Hansen, Anna Maria Dittrich, Burkhard T ümmler, Manuel Nietert Tags: Original article Source Type: research

Achieving respiratory excellence in pre-school children with cystic fibrosis
A child with cystic fibrosis (CF) who begins school at 5-6 years of age in good respiratory health has established a strong framework for the rest of their life. Respiratory excellence has been achieved if a child is active and asymptomatic with normal chest radiology and a lack of CF pathogens from respiratory cultures. To achieve this goal, excellent nutrition is imperative and there is clear consensus on the approach to address pancreatic insufficiency [1]. This contrasts with airway management strategies, which are extremely variable across the globe. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 20, 2021 Category: Respiratory Medicine Authors: Kevin W Southern Tags: Editorial Source Type: research

1: Glycemic control in patients with cystic fibrosis –related diabetes before and after elexacaftor/tezacaftor/ivacaftor
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: C. Wood, M. Meier, A. Granados, E. Towler, E. Findlay, C. Chan Tags: Posters Source Type: research

2: Oral glucose tolerance testing using candy: A sweet solution to improve screening compliance in cystic fibrosis?
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: C. Weeks, C. Pyrz, J. Olson, V. Dean, S. Jackson, N. Demirel, A. Creo Tags: Posters Source Type: research

3: Vitamin D status and cystic fibrosis –related diabetes: A retrospective chart review
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: Y. Peng, T. Gunawardana, M. Wu, J. Alvarez, V. Tangpricha Tags: Posters Source Type: research

4: The effect of elexacaftor/tezacaftor/ivacaftor on glycemia in adults with cystic fibrosis: A prospective continuous glucose monitoring study
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: K. Scully, P. Marchetti, G. Sawicki, A. Uluer, M. Cernadas, R. Cagnina, J. Kennedy, M. Putman Tags: Posters Source Type: research

5: Testosterone deficiency in men with cystic fibrosis: Understanding prevalence & association with clinical outcomes
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: N. Puri, J. Sykes, E. Tullis, J. Gilmour Tags: Posters Source Type: research

6: Effect of triple-modulator therapy on glucose utilization in patients with cystic fibrosis
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: C. Stang, C. Nemastil, A. Patel, M. Eisner, S. Bai, K. Novak Tags: Posters Source Type: research

7: Reduced trabecular bone growth in an adolescent female cystic fibrosis rat model
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: M. Awadalla, E. Perilli, S. Martelli, K. Morgan, M. Kitchen, P. Cmielewski, A. McCarron, D. Parsons, M. Donnelley Tags: Posters Source Type: research

8: SGLT1/2 inhibitor sotagliflozin attenuates pancreatic endoplasmic reticulum stress through IRE1 α/XBP1 pathway in cystic fibrosis rabbits
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: Y. Sun, X. Liang, X. Hou, M. Bouhamdan, J. Song, Y. Chen, J. Jin, J. Xu Tags: Posters Source Type: research

9: Pancreatic and islet vasculature are significantly diminished in CF donors – a potential contributor to insulin deficiency in CF
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: J. Castillo, A. Aplin, R. Akter, R. Hull-Meichle Tags: Posters Source Type: research

10: Satisfaction and concerns with telemedicine endocrine care of patients with cystic fibrosis
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: M. Desimone, R. Ahmed, M. Greenfield Tags: Posters Source Type: research

11: A novel method to detect CF-related diabetes using changes in voice characteristics
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: P. Suppakitjanusant, N. Kasemkosin, B. Ongphiphadhanakul, S. Weinstein, W. Hunt, V. Sueblinvong, V. Tangpricha Tags: Posters Source Type: research

12: Changes in bone turnover markers following hospital admission for acute pulmonary exacerbation in adults with CF
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: A. Bhimavarapu, M. Wu, J. Alvarez, W. Hunt, V. Tangpricha Tags: Posters Source Type: research

13: Plasma acylcarnitines in adult cystic fibrosis and relationships with body composition and glucose tolerance
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: B. Cousineau, E. Ivie, P. Nesbeth, K. Taibl, M. Bellissimomyers, J. Chandler, K. Easley, V. Tangpricha, W. Hunt, A. Stecenko, T. Ziegler, J. Alvarez Tags: Posters Source Type: research

14: Pregnancy and outcomes in the era of CFTR modulators and COVID-19 pandemic
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: S. Li, A. Patel, J. Heintz, A. Nance, A. Rice, K. Sakellaris, S. Gemma, S. Pedigo Blanton, M. Johnson, E. Stephan, S. Kirkby Tags: Posters Source Type: research

15: Association of estrogen supplementation with bone turnover markers in women with cystic fibrosis
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: M. Wu, W. Hunt, V. Tangpricha Tags: Posters Source Type: research

16: Continuous glucose monitors in CFRD screening: What can they do?
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: K. Kutney, T. Casey, M. O ’Riordan Tags: Posters Source Type: research

17: Development of metabolic syndrome in a single-center cohort after initiation of elexacaftor/tezacaftor/ivacaftor
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: G. Ratti, A. Rueschhoff, J. Reisch, K. Lowe, S. Jian, L. Cohen, S. Mirfakhraee, R. Jain, J. Finklea Tags: Posters Source Type: research

18: Effect of clinical initiation of elexacaftor/tezacaftor/ivacaftor on glucose homeostasis in patients with cystic fibrosis
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: A. Granados, A. Moheet, C. Chan, S. Singh, A. Norris, S. Hu, Y. Yi, K. Larson Ode Tags: Posters Source Type: research

19: Glycemic response to exercise in patients with cystic fibrosis –related diabetes
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: A. Singhal, Q. Duong, K. Ahmad, M. Bowen, A. Brown, C. King Tags: Posters Source Type: research

20: Performance of a statistical model in predicting cystic fibrosis –related diabetes (CFRD) utilizing genetic and non-genetic risk factors
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: M. Porter, M. Aksit, S. Blackman Tags: Posters Source Type: research

21: Review of glycaemic control, nutritional status and lung function after initiation of flash glucose monitoring for patients with cystic fibrosis –related diabetes
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: L. Sheibani, M. Dunnage, N. Shafi, D. Watson Tags: Posters Source Type: research

22: Unique challenges of treating women with cystic fibrosis –related diabetes in pregnancy
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: E. Siegler, M. Litvin Tags: Posters Source Type: research

23: CFTR modulators and new bacterial acquisition: A registry-based analysis using data from the CFFPR
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: S. Singh, A. Fischer Tags: Posters Source Type: research

24: Adults with CF, caregivers, and clinicians differ regarding perceptions of pain and symptom prevalence and distress: Results of a national survey
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: E. Dubin, E. Dellon, J. Lowers, S. Hempstead, A. Faro, E. Tallarico, D. Kavalieratos Tags: Posters Source Type: research

25: Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children and adolescents with cystic fibrosis
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: G. Hergenroeder, J. Cogen, A. Genatossio, S. McNamara, M. Pascual, R. Hernandez Tags: Posters Source Type: research

26: Caregiver depression and anxiety prevalence in cystic fibrosis: A systematic review and meta-analysis investigating epidemiology
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: L. Lord, D. McKernon, L. Grzeskowiak, S. Kirsa, J. Ilomaki Tags: Posters Source Type: research

27: You down with OCPs? Well, you tell me
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: R. Auth, S. Rhoads, D. Banerjee, M. Stephens, M. Blundin, K. Powers Tags: Posters Source Type: research

28: Treatment characteristics for children with cystic fibrosis and meconium ileus admitted within the first 14 days of life
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: J. Gonzales Cordova, J. Slaven, J. Saunders, C. Ren, D. Sanders Tags: Posters Source Type: research

29: Utilizing latent class mixed models to identify patterns in lung function in children with CF
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: C. Goss, E. Cromwell, J. Ostrenga, A. Fink, W. Morgan Tags: Posters Source Type: research

30: Association between gaps in care and lung function decline in the U.S. CF Foundation Patient Registry
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: E. Sears, A. Hinton, C. Lary, J. Zuckerman Tags: Posters Source Type: research

31: Epidemiology and CFTR genotype analysis of Asians in international registries highlights disparities in the diagnosis and treatment of Asian CF patients
(Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - October 18, 2021 Category: Respiratory Medicine Authors: S. Vaidyanathan, A. Trumbull, L. Bar, M. Rao, Y. Yu, Z. Sellers Tags: Posters Source Type: research